Meet the Veristat team at Booth #47, April 16th and 17th in Berlin.
Webinar: Advancing Development of New Oncology Therapies: Aligning with FDA’s Project FrontRunner
March 14, 2024
Thursday, April 4 | 11am EDT | 1 hour | Hosted by: Clinical Leader
In November 2022, FDA Oncology Center of Excellence (OCE) introduced Project FrontRunner to emphasize the need for new cancer drugs to be accessible to patients with early advanced metastatic cancer in an earlier clinical setting. The aim is to provide an alternative development pathway for faster approval of new treatments that does not follow the existing paradigm in which most treatments are developed for patients who have already received multiple prior lines of therapy or have failed available treatment options. Eligible development programs should have the potential to provide clinically meaningful treatment effects and/or have better safety profiles than the current “standards of care.”
Cell & Gene Meeting on the Med 2024, an ARM Conference
March 11, 2024
Meet Veristat in Rome at the Meeting on the Med Conference 2024, 9-11 April 2024
BIO-Europe Spring 2024
March 6, 2024
Meet Veristat in Barcelona at BIO-Europe Spring 2024, 18-20 March 2024
35th Pharmacovigilance USA Conference 2024
March 6, 2024
Meet Veristat in Boston at the Pharmacovigilance USA Conference
2-3 May 2024
TOPRA Symposium 2024
February 14, 2024
Meet Veristat at the TOPRA Symposium 2024, 30 September - 2 October, Rotterdam, the Netherlands, Booth 23
World Orphan Drug Congress EUROPE 2024
February 14, 2024
Veristat is excited to announce its participation in this year's World Orphan Drug Congress Europe, held in Barcelona, 22 - 25 October 2024
World Orphan Drug Congress USA
January 30, 2024
Veristat is excited to announce its participation in this year's World Orphan Drug Congress, held in Boston, 23 -25 April 2024